期刊文献+

地西他滨联合半量CAG方案治疗急性髓细胞白血病的护理 被引量:8

Nursing care of decitabine combined with half amount of CAG program for treatment of patients with acute myeloid leukemia
下载PDF
导出
摘要 [目的]总结地西他滨联合半量CAG方案治疗急性髓细胞白血病的护理。[方法]对16例急性髓细胞白血病病人采用地西他滨联合半量CAG方案治疗,同时加强心理护理、不良反应的护理。[结果]完全缓解(CR)8例和部分缓解(PR)3例,未缓解5例;发生不良反应中感染6例,胃肠道反应4例,出血2例。[结论]加强心理护理和不良反应的护理,是急性髓细胞白血病病人采用地西他滨联合半量CAG方案治疗成功的保证。 Objective. To summarize the nursing care of decitabine combined with half amount of CAG program for treatment of patients with acute myeloid leukemia. Methods. A total of 16 cases of acute myeloid leukemia patients were treated by decitabine combined with half amount of CAG program,at the same time,the mental nursing and care of adverse reaction were strengthened for them. Results. There were 8 cases of complete remission and 3 cases of partial remission. There were also 5 cases of non - remission, and 6 cases of infection in adverse reactions. Conclusion. To strengthen mental nursing and care of ad- verse reaction is the guarantee of decitabine combined with half amount of CAG program for treatment of patients with acute myeloid leukemia.
作者 陈颖颖
出处 《全科护理》 2012年第10期881-882,共2页 Chinese General Practice Nursing
关键词 地西他滨 急性髓细胞白血病 护理 decitabine acute myeloid leukemia nursing
  • 相关文献

参考文献6

二级参考文献39

共引文献89

同被引文献61

  • 1柳金,陆道培,张艳.急性红白血病55例染色体特征和预后分析[J].中华内科杂志,2006,45(9):738-740. 被引量:9
  • 2杨薇,陈银海,崔恒宓.地西他滨和5-阿扎胞苷在癌症研究及临床上的应用[J].中国药学杂志,2006,41(21):1601-1605. 被引量:5
  • 3曾蓉,陈燕.急性红白血病的生物学特征与临床疗效研究[J].中国实验血液学杂志,2007,15(3):466-469. 被引量:11
  • 4Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996.
  • 5张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281.
  • 6Saba HI. Decitabine in the treatment of myelodysplastic syn- dromes. Ther Clin Risk Manag, 2007 ;3 (5) : 807 -817.
  • 7Qin T, Castoro R, E1 AS, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One, 2011 ; 6 (8) : 23372 -23382.
  • 8Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treaanent (ADOPT) trial. J Clin Oncol, 2009 ; 27 ( 23 ) : 3842 - 3848.
  • 9Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma,2008 ;49(4) : 690 - 695.
  • 10Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther, 2010;10(1) : 9 -22.

引证文献8

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部